๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pediatric cancer in the United States. A preliminary report of a collaborative study of the childrens cancer group and the pediatric oncology group

โœ Scribed by Julie A. Ross; Richard K. Severson; Leslie L. Robison; Brad H. Pollock; Joseph P. Neglia; William G. Woods; G. Denman Hammond


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
555 KB
Volume
71
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Background:

Cancer is the second leading cause of death in children younger than 15 years. although 5-year survival rates have increased dramatically for many childhood tumors, more than 100,000 person-years of life are lost to childhood cancer each year. the exact proportion of pediatric patients with cancer who receive care at centers that use up-to-date therapeutic protocols (such as those affiliated with the childrens cancer group (ccg) or the pediatric oncology group (pog) is unknown.

Methods:

Based on residence at the time of diagnosis, observed numbers of pediatric cancer cases seen by member institutions of the ccg and the pog in 1989 and 1990 were compared with the expected number of cases. expected values were calculated from incidence rates obtained from the surveillance, epidemiology and end results program and population counts obtained from the us census bureau.

Results:

Results indicate that more than 90% of children younger than 15 years who have a diagnosis of malignant neoplasm are seen at an institution that is a member of either ccg or pog. the highest proportion seen occurs in the youngest (0-4 years) age group, and the proportion declines steadily with increasing age.

Conclusions:

There are specific regions within the united states where the observed number of cases was substantially less than the expected number, including areas of texas, idaho, and virginia. although the exact reasons for these potential deficits are unknown, additional study of these areas is recommended.


๐Ÿ“œ SIMILAR VOLUMES


Phase I/II study of bisantrene in childh
โœ Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 328 KB

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect

Childhood cancer in the united states: A
โœ Julie A. Ross; Richard K. Severson; Brad H. Pollock; Leslie L. Robison ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 648 KB

## BACKGROUND. After injuries, cancer is the leading cause of death in children younger than 15 years in the IJnited States. Despite dramatic increases in .?-year survival rates, more than 100,000 person-years of life are lost to childhood cancer each year. 'The exact proportion of pediatric cance